Equities

Milestone Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MIST:NSQ

Milestone Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.70
  • Today's Change-0.02 / -1.16%
  • Shares traded1.56m
  • 1 Year change-25.76%
  • Beta0.4857
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

  • Revenue in USD (TTM)0.00
  • Net income in USD-58.01m
  • Incorporated2003
  • Employees33.00
  • Location
    Milestone Pharmaceuticals Inc420-1111 boul. Dr.-Frederik-PhilipsMONTREAL H4M 2X6CanadaCAN
  • Phone+1 (514) 336-0444
  • Fax+1 (514) 336-0444
  • Websitehttps://www.milestonepharma.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sangamo Therapeutics Inc32.88m-108.91m138.20m183.00--19.96--4.20-0.4428-0.44280.13260.01940.3289--5.97179,644.80-108.96-30.73-204.29-37.33-----331.28-147.59----0.00---67.20-10.8162.01---58.10--
HST Global Inc0.00-212.63k139.70m1.00--8.48-----0.0107-0.01070.000.11670.00-------6.87-27.80-8.09-60.19-----------107.480.0433-------45.42------
Nkarta Inc0.00-102.61m139.93m105.00--0.4141-----1.39-1.390.004.760.00----0.00-21.39-29.78-22.36-31.23------------0.00------7.41--17.99--
Prelude Therapeutics Inc10.50m-111.77m140.19m131.00--2.16--13.35-1.47-1.470.13821.030.0719----80,152.67-76.56-47.36-88.86-51.44-----1,064.50-7,615.23----0.00-------4.38---0.4137--
Tenaya Therapeutics Inc0.00-94.26m141.07m97.00--1.30-----0.7875-0.78750.000.50610.00----0.00-76.77-47.44-87.21-51.82------------0.00------10.44---18.92--
Fate Therapeutics Inc7.14m-156.09m144.19m181.00--0.616--20.20-1.32-1.320.06032.030.017--2.3039,430.94-37.23-32.44-40.38-36.57-----2,187.11-389.06----0.00---78.555.00-15.74---37.07--
Milestone Pharmaceuticals Inc0.00-58.01m144.79m33.00--7.06-----0.8938-0.89380.000.24070.00----0.00-68.07-48.63-75.01-52.10-------1,201.96---73.280.7327---100.00--30.44---39.67--
Connect Biopharma Holdings Ltd (ADR)762.00k-50.77m145.35m62.00--2.62--190.75-0.9144-0.91440.01370.9926------12,290.32---61.12---66.78-----6,662.99-1,963.00----0.00------74.84--37.04--
Microbot Medical Inc0.00-13.07m145.73m21.00--1.83-----0.4513-0.45130.001.190.00----0.00-30.06-67.69-31.62-80.15------------0.00-------6.55---35.03--
Caribou Biosciences Inc9.30m-157.13m147.68m147.00--1.04--15.89-1.70-1.700.10041.520.0345--6.5763,231.29-58.27-30.69-65.59-33.30-----1,690.45-562.81----0.00---71.0111.54-46.08--40.73--
Angion Biomedica Corp0.00-45.86m149.54m32.00--38.67-----3.15-3.150.000.22110.00----0.00-137.56-106.87-179.35-289.86-------778.01---302.490.7181-------47.46---18.50--
Rani Therapeutics Holdings Inc1.20m-28.32m150.69m105.00------125.57-0.7906-0.79060.0322-0.10930.0447----11,428.57-177.34-64.50-603.19-106.31-----3,966.50-6,123.18---14.328.66----0.981611.63---29.88--
Acumen Pharmaceuticals Inc0.00-133.35m152.04m61.00--1.63-----2.21-2.210.001.540.00----0.00-65.18-33.77-72.61-35.61-------21,273.47----0.2475-------95.39------
Century Therapeutics Inc113.34m-26.48m152.96m140.00--0.8587--1.35-0.3086-0.30861.322.040.3579----809,550.00-8.36-33.69-8.95-36.94-----23.36-3,876.28----0.00--194.81--7.40---42.55--
Data as of Feb 13 2026. Currency figures normalised to Milestone Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

28.51%Per cent of shares held by top holders
HolderShares% Held
Adage Capital Management LPas of 30 Sep 20256.98m8.19%
Propel Bio Management LLCas of 31 Dec 20254.12m4.84%
Trails Edge Capital Partners LPas of 30 Sep 20253.83m4.50%
RTW Investments LPas of 30 Sep 20252.51m2.94%
Marshall Wace LLPas of 31 Dec 20251.66m1.95%
Simplify Asset Management, Inc.as of 31 Dec 20251.51m1.77%
Jane Street Capital LLCas of 31 Dec 20251.09m1.28%
Pathstone Family Office LLCas of 31 Dec 20251.02m1.19%
Sphera Funds Management Ltd.as of 30 Sep 2025820.00k0.96%
Cowen Financial Products LLCas of 30 Sep 2025750.00k0.88%
More ▼
Data from 30 Sep 2025 - 03 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.